Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$5.77B+23.93%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard Saynor
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 23,000
- Beta
- 0.49
- Country
- CH
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 3.42
Financials
SDZNY has only 9 quarterly periods on file — the charts below show the full history available.
Revenue
$5.77B+23.9%Net Income
$109.24M-76.7%EBITDA
$1.12B+22.3%Free Cash Flow
$606.31M+180.4%EPS (diluted)
$0.25-54.5%Shares Outstanding (diluted)
438.40M+2.0%Operating Expenses
$1.88BCash & Debt
$1.25BReturn of Capital
$445.96MDividend per Share
$1.02Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.15B | $919.12M | $2.13 |
| 2024 | $10.38B | $1.00M | $0.00 |
| 2023 | $11.66B | $89.99M | $0.21 |
| 2022 | $9.30B | $847.75M | $1.97 |
| 2021 | $9.62B | $907.82M | $2.11 |
| 2020 | $9.67B | $490.46M | $1.14 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SDZNY's reported EPS growth of 13.3% a year over 5 years.
- EPS in 5 years
- $3.98
- Implied price
- $135.33
- Return from $82.86
- 10.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $67.28 — -18.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 24 | 29 | 34 | 39 | 44 |
|---|---|---|---|---|---|
| 3.3% | -6.2% | -2.6% | 0.6% | 3.4% | 5.9% |
| 8.3% | -1.7% | 2.1% | 5.4% | 8.4% | 11.0% |
| 13.3% | 2.9% | 6.9% | 10.3% | 13.4% | 16.1% |
| 18.3% | 7.4% | 11.6% | 15.2% | 18.4% | 21.3% |
| 23.3% | 12.0% | 16.3% | 20.0% | 23.4% | 26.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+1100.00%Social Signal Score
Mentions (5)
- Newsprnewswire.com·18d ago·Negative
mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases.
View source ↗ - Newswsj.com·18d ago·Negative
Sandoz Gets Canada Approval for Generic Version of Ozempic The approval for its generic version of diabetes drug Ozempic advances its efforts to build a portfolio of GLP-1 medicines.
View source ↗ - Newsreuters.com·28d ago·Negative
Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its focus from generics to biosimilars.
View source ↗ - Newsprnewswire.com·50d ago·Negative
…RNewswire/ -- On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.
View source ↗ - Newsreuters.com·50d ago·Negative
Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech Swiss generic drugmaker Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday.
View source ↗
Congress trades
- John Wright Hickenloopersenate · CO · disclosed May 15, 2025 (492d later)Sell$1,001 - $15,000
- George Whitesideshouse · CA27 · disclosed Apr 23, 2025 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (26d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.